Albuminuria: The CKM biomarker we’re overlooking❗️. 💡The best risk stratifying biomarker. 🔹 Even UACR <3.4 mg/mmol = ⤴️ #CVD, #CKD & mortality risk. 🔸 Signals early endothelial dysfunction across HTN, #T2D, #HF & #MASLD. 🔹 Yet 💧screening rates low, esp. in primary care. 🔸

RT @kamleshkhunti: Why Do Patients Discontinue GLP-1 Medications for Obesity?. Adherence Challenges.❌ 50% stop treatment within 6 months. T….

RT @kamleshkhunti: Improving Affordability of Diabetes Medications: A Global Call to Action. 🔹 1 in 10 people globally has diabetes.🔹 Milli….

RT @kamleshkhunti: 🧪 De-intensifying diabetes meds RCT .📍 @JAMA_current . Older adults with type 2 diabetes. 🧰 Intervention.✅ Academic Det….

RT @AbdTahrani: I had the pleasure of coauthing this paper with the brilliant @DJPournaras and amaizing access team at Novo Nordisk. The p….

🧾 GLP-1 vs SGLT2: Same Admissions, Higher Costs?. New real-world data (n = 44K, Medicare Advantage):. 📌 12-month follow-up. 👥 Age: 68y avg | 52% female | 46% ASCVD | 56% obesity. 💉 GLP-1 RA vs SGLT2i:. • 🏥 No difference in inpatient stays or ED visits.• 💸 +9% pharmacy

RT @kamleshkhunti: GLP-1 receptor agonists associated with fewer kidney and heart events in people with T2 diabetes and advanced CKD. https….

RT @markinho_gc: 🔰Recomendaciones de consenso de la Sociedad de Diabetes en el Embarazo de Australasia (ADIPS) para la detección, el diagn….

RT @DSNforumUK: NEW 4-part special podcast series ✨ . Episode 2️⃣. Join us & @drpatrickholmes for a deep dive into injection technique acro….

RT @kamleshkhunti: People with obesity have a higher prevalence and incidence & accelerated onset of obesity related complications compared….

RT @parthaskar: As promised. Episode 3 of 'KarMic'. The upcoming #NHS10YearPlan; the cult like devotion to 'The Three fundamental Shifts….

🚨 MariTide – Once-Monthly Incretin Hits Hard 🚨. Maridebart cafraglutide (MariTide), a GLP-1RA + GIP antagonist, delivered double-digit weight loss — but at a GI cost. 🔬 Phase 2 (n=592).✅ Monthly 💉.• #obesity -only cohort: weight ⤵️ 12.3–16.2%.• Obesity + #T2D cohort:.🩸

RT @parthaskar: Today? #Mounjaro is launched into the #NHS . Link: My views on it via @bmj_latest . It now opens u….

🚨🦵 Semaglutide "STRIDE's" ahead in PAD". In people with PAD + T2D, semaglutide improved walking capacity regardless of:. 📊 Duration of diabetes.🍩 HbA1c levels.⚖️ Obesity status.💉 SGLT2i or insulin use. 🔹 MWD ↑ by 22–63m.🔹 PFWD ↑ by 16–47m.🔹 Effects not explained by

#ADA2025: PG-110 + Semaglutide – Boosted Fat Loss, Bone Gains 💪🦴🔥. Bispecific antibody (ActRII + myostatin) enhances fat-specific weight loss in obese mice without lean mass loss. 🧪 DIO 🐁 model (pre-clinical❗️).💉 PG-110 (QW) + Sema (QD) for 2 wks. ⚖️ Sema alone ↓ BW.➕

#ADA2025: Eloralintide – Long-Acting Amylin Enters the Arena 💉. Once-weekly amylin receptor agonist shows early weight loss signal with good tolerability✅. 🔬Phase 1 (n=100; BMI 27–43).📊 Doses: 5 cohorts of QW SC injections vs placebo. ⚖️ Mean WL at 12 wks (LS): −2.6% to

#ADA2025: Who’s Eligible for GLP-1 Therapy Globally? 🌍. First global estimates from 773,513 adults across 91 countries – sobering thought 🇵🇰‼️. 📊 27.6% eligible (≈750M people). • 66% based on BMI alone. • Higher in rich nations (44%) vs poor (11.5%). • Poorest quintile:

RT @cristinatejerap: Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity | New England Journal of Medicine htt….

🚨CagriSema REDEFINEing #T2D care❓🚨. Amylin + GLP-1 combo leads to −13.7% WL and −1.8% HbA1c at 68 weeks. 🧪 Phase 3a, 68-week RCT (n=1206; BMI ≥27, HbA1c 7–10%). 💉 QW Cagrilintide 2.4 mg + Semaglutide 2.4 mg. 🎯 HbA1c ≤6.5%: 73.5% vs 15.9%.🎯 ≥5% WL: 83.6% (CagriSema) vs